Pacira BioSciences (NASDAQ:PCRX) on Thursday announced that the U.S. Centers for Medicare and Medicaid Services (CMS) issued a product-specific J-code for its non-opioid pain therapy Exparel for ...
Please provide your email address to receive an email when new articles are posted on . Ycanth has received a permanent J-code for the treatment of molluscum contagiosum. The code will be fully ...
Pacira BioSciences PCRX announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code (J0666) for its lead pain-management drug, Exparel ...
How a strong collaboration between clinical and billing teams can simplify J-code decoding, paving the way for improved patient access to innovative treatments. It’s an all-too-common story. A patient ...
NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today ...
Hosted on MSN
UroGen outlines $1B ZUSDURI peak revenue ambition as adoption set to accelerate with permanent J-code in 2026
CEO Elizabeth Barrett highlighted the progress of the ZUSDURI launch and noted, "The preliminary demand revenue for October is more than double the previous 3 months, demonstrating increased usage and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results